D. E. Shaw & Co., Inc. Exact Sciences Corp Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 6,200 shares of EXAS stock, worth $267,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,200

Previous 10,000 38.0%

Holding current value

$267,778

Previous $739,000 42.08%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $5.58 Million - $7.31 Million	99,127 Added 435.78%	121,874 $8.42 Million
Q4 2023 Feb 14, 2024	SELL	$59.06 - $75.72 $8.64 Million - $11.1 Million	-146,359 Reduced 86.55%	22,747 $1.68 Million
Q3 2023 Nov 14, 2023	BUY	$65.94 - $99.04 $11 Million - $16.5 Million	166,606 Added 6664.24%	169,106 $11.5 Million
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $465,022 - $705,175	-7,419 Reduced 74.8%	2,500 $234,000
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $6.36 Million - $9.53 Million	-134,713 Reduced 93.14%	9,919 $672,000

Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $808,615 - $1.42 Million	-26,643 Reduced 15.56%	144,632 $7.16 Million
Q3 2022 Nov 14, 2022	SELL	$31.97 - $49.37 $415,801 - $642,106	-13,006 Reduced 7.06%	171,275 $5.57 Million
Q2 2022 Aug 15, 2022	BUY	$35.61 - $76.23 $4.89 Million - $10.5 Million	137,309 Added 292.32%	184,281 $7.26 Million
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $2.91 Million - $4.17 Million	-50,478 Reduced 51.8%	46,972 $3.28 Million
Q4 2021 Feb 14, 2022	SELL	$72.5 - $100.68 $3.63 Million - $5.04 Million	-50,068 Reduced 33.94%	97,450 $7.59 Million
Q3 2021 Nov 15, 2021	SELL	$90.24 - $124.05 $5.44 Million - $7.47 Million	-60,241 Reduced 29.0%	147,518 $14.1 Million
Q2 2021 Aug 16, 2021	SELL	$93.66 - $139.27 $22.3 Million - $33.1 Million	-237,622 Reduced 53.35%	207,759 $25.8 Million
Q1 2021 May 17, 2021	BUY	$116.57 - $155.01 $24.1 Million - $32.1 Million	207,079 Added 86.9%	445,381 $58.7 Million
Q4 2020 Feb 16, 2021	BUY	$99.61 - $142.12 $21.6 Million - $30.9 Million	217,319 Added 1035.69%	238,302 $31.6 Million
Q3 2020 Nov 16, 2020	SELL	$72.92 - $102.01 $525,461 - $735,084	-7,206 Reduced 25.56%	20,983 $2.14 Million
Q2 2020 Aug 14, 2020	BUY	$55.75 - $92.75 $632,651 - $1.05 Million	11,348 Added 67.38%	28,189 $2.45 Million
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $17.4 Million - $48.1 Million	-460,403 Reduced 96.47%	16,841 $977,000
Q4 2019 Feb 14, 2020	SELL	$77.66 - $99.74 $44.4 Million - $57.1 Million	-572,155 Reduced 54.52%	477,244 $44.1 Million
Q3 2019 Nov 14, 2019	SELL	$90.37 - $122.49 $52.8 Million - $71.5 Million	-583,763 Reduced 35.74%	1,049,399 $94.8 Million
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $77.3 Million - $102 Million	-863,588 Reduced 34.59%	1,633,162 $193 Million
Q1 2019 May 15, 2019	BUY	$61.98 - $96.5 $43 Million - $66.9 Million	693,159 Added 38.43%	2,496,750 $216 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $29.3 Million - $43.1 Million	521,953 Added 40.73%	1,803,591 $114 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $99.3 Million - $166 Million	-2,055,467 Reduced 61.59%	1,281,638 $101 Million
Q2 2018 Aug 14, 2018	BUY	$37.84 - $69.96 $21.9 Million - $40.5 Million	579,440 Added 21.01%	3,337,105 $200 Million
Q1 2018 May 15, 2018	SELL	$39.82 - $57.53 $25.4 Million - $36.7 Million	-638,738 Reduced 18.81%	2,757,665 $111 Million
Q4 2017 Feb 14, 2018	SELL	$46.49 - $60.51 $31.9 Million - $41.6 Million	-686,815 Reduced 16.82%	3,396,403 $178 Million
Q3 2017 Nov 14, 2017	BUY	$37.05 - $47.12 $151 Million - $192 Million	4,083,218	4,083,218 $192 Million

Others Institutions Holding EXAS

# of Institutions

699

Shares Held

160M

Call Options Held

5.84M

Put Options Held

2.58M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $7.64B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account